Compositions and methods for inhibiting the activity of LAR family phosphatases
A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.
1. A therapeutic agent, comprising:
a therapeutic peptide comprising an amino acid sequence with at least 70% identity to SEQ ID NO:37 and a transport moiety linked to the therapeutic peptide and facilitates uptake of the therapeutic peptide by a cell.
2. The therapeutic agent of claim 1 , wherein the amino acid sequence has at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to SEQ ID NO:37.
3. The therapeutic agent of claim 1 , wherein the therapeutic peptide comprises a substitution of an amino acid of at least one of residue 4, 5, 6, 7, 9, 10, 12, or 13 of SEQ ID NO: 37 for another amino acid, wherein the amino acid residue 4E is substituted with D or Q, amino acid residue 5R is substituted with H, L or K, amino acid residue 6L is substituted with I, V or M, amino acid residue 7K is substituted with R or H, amino acid residue 9N is substituted with E or D, amino acid residue 10D is substituted with E or N, amino acid residue 12L is substituted with I, V or M, and/or amino acid residue 13K is substituted with R or H.
4. The therapeutic agent of claim 1 , wherein the therapeutic peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:9-33 and 37.
5. The therapeutic agent of claim 1 , wherein the transport moiety is an HIV Tat transport moiety.
6. The therapeutic agent of claim 1 , wherein the transport moiety is linked to the therapeutic peptide by a peptide linker.
7. The therapeutic agent of claim 1 , wherein the therapeutic agent comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:42-66 and 70.
8. The therapeutic agent of claim 1 , wherein the therapeutic peptide inhibits one or more of catalytic activity, signaling, or function of protein tyrosine phosphatase sigma (PTPσ).
9. A method of treating a neurological injury or disorder in a subject in need thereof, the method comprising:
administering to the subject a therapeutic agent as recited in claim 1 .
10. The method of claim 9 , wherein the therapeutic agent inhibits one or more of catalytic activity, signaling, and/or function of receptor protein tyrosine phosphatase sigma (PTPσ).
11. The method of claim 9 , wherein neurological injury or disorder comprises at least one of Alzheimer's disease, dementias related to Alzheimer's disease, Parkinson's disease, Lewy diffuse body diseases, senile dementia, Huntington's disease, Gilles de la Tourette's syndrome, multiple sclerosis, amyotrophic lateral sclerosis, hereditary motor and sensory neuropathy, diabetic neuropathy, progressive supranuclear palsy, epilepsy, or Jakob-Creutzfieldt disease.
12. The method of claim 9 , wherein the neurological injury or disorder is a peripheral injury or disorder.
13. The method of claim 9 , wherein the peripheral injury or disorder is a urinary bladder disorder.
14. The method of claim 9 , wherein the therapeutic agent is administered systemically.
15. The method of claim 9 , wherein the therapeutic agent therapeutic peptide comprising an amino acid sequence with at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to SEQ ID NO:37.
16. The method of claim 9 , wherein the therapeutic peptide comprises a substitution of an amino acid of at least one of residue 4, 5, 6, 7, 9, 10, 12, or 13 of SEQ ID NO: 37 for another amino acid, wherein the amino acid residue 4E is substituted with D or Q, amino acid residue 5R is substituted with H, L or K, amino acid residue 6L is substituted with I, V or M, amino acid residue 7K is substituted with R or H, amino acid residue 9N is substituted with E or D, amino acid residue 10D is substituted with E or N, amino acid residue 12L is substituted with I, V or M, and/or amino acid residue 13K is substituted with R or H.
17. The method of claim 9 , wherein the therapeutic peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:9-33 and 37.
18. The method of claim 9 , wherein the transport moiety is an HIV Tat transport moiety.
19. The method of claim 9 , wherein the therapeutic agent comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:42-66 and 70.